ClinicalTrials.gg
CompletedNCT03826628Updated Sep 8, 2023Results posted

Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex

A Phase 2/3 interventional study of rapamycin and placebo in Facial Angiofibroma and Tuberous Sclerosis, sponsored by Dermatology Specialties Limited Partnership. Completed at 17 sites in 9 countries. Open to participants aged 6 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-08.

Sponsored by Dermatology Specialties Limited Partnership · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
6 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing sirolimus in Tuberous Sclerosis — 1 open to participants now, 2 under way, 1 of them phase 3. Sirolimus · Tuberous Sclerosis.

Enrollment
2nd of 12
107 · median 31
Started
2019
the only one that year
Phase 2/3
2 of 12
1 open now
Registered
9th of 12
by date
Lead sponsor
1 of 12
Dermatology Specialties Limited Partnership

Among the 12 studies testing sirolimus in Tuberous Sclerosis, this one is the 2nd largest by enrollment, is the only one that started in 2019, is one of 2 in phase 2/3, and was the 9th registered.

Tuberous Sclerosis

115 studies on the registry are indexed under Tuberous Sclerosis; 27 are open to participants now.

Browse Tuberous Sclerosis studies →

Open to participants now

1 of the 12 studies testing sirolimus in Tuberous Sclerosis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About sirolimus

Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 21 Tuberous Sclerosis studies recruiting now, 10 (48%) set no upper age limit and 8 (38%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 6 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing sirolimus in Tuberous Sclerosis, or all of them as a file.
02

Study summary

The study aims to compare the safety and efficacy of two different strengths of Rapamycin cream, topical and placebo over 26 weeks in the treatment of facial angiofibroma (FA) associated with Tuberous Sclerosis Complex (TSC).

Read the detailed description

Topical rapamycin has previously been used to treat FA associated with TSC, reducing erythema, papule size, while flattening lesions and improving skin texture. Topical rapamycin has been reported to be well tolerated.

The efficacy and safety of a topical rapamycin cream at two strengths (0.5% and 1.0%) will be assessed during a 26 week double-blind treatment phase with assessments made at clinical visits at baseline, 2, 8, 14, 20 and 26 weeks, and at follow-up (4 weeks after the last dose of study drug).

03

Conditions studied

  • Facial Angiofibroma
  • Tuberous Sclerosis

Browse trials for

04

Who can participate

Ages eligible
6 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients aged ≥ 6 years and ≤ 65 years on the day is obtained
  2. Patients diagnosed with TSC based on the clinical diagnostic criteria of International Tuberous Sclerosis Complex Consensus Conference 2012 and presenting visible facial angiofibroma
  3. An FA severity score of 2 or 3 on the IGA scale
  4. Patients or their legal representatives capable of understanding the explanation of the clinical trial and who give written informed consent for participation
  5. Patients or their legal representatives able to maintain patient diaries following the instructions of the investigator or sub-investigator

Exclusion criteria

Exclusion Criteria:

  1. Patients who cannot carry out the treatment plan or follow-up assessment
  2. Patients with serious skin lesions such as erosions or ulcers
  3. Patients with known to any component of the study product
  4. Patients who have received rapamycin/sirolimus, everolimus, or temsirolimus within 3 months of enrolment
  5. Patients who received laser therapy or surgical therapy within 6 months prior to trial enrolment
  6. Patients who participated in any other clinical trial within 3 months prior to the day of enrolment
  7. Patients judged unsuitable for this clinical trial by the investigator or sub-investigator
  8. Pregnant or lactating females
  9. Sexually active females of not using adequate and sexually active males not using adequate contraception
  10. Patients with immune dysfunction or receiving any form of
  11. Patients with severe FA, with a score of 4 on the IGA scale
  12. Patients with an FA severity score of less than 2 on the IGA scale
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    0.5% Rapamycin cream, topical

    Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks

    Drug: rapamycin

  • Experimental
    1.0% Rapamycin cream, topical

    Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks

    Drug: rapamycin

  • Placebo comparator
    Placebo

    Placebo cream topical, applied once daily before bed on affected area for 26 weeks

    Drug: placebo

Interventions

  • Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks

    Also known as: sirolimus

  • Drugplacebo

    Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Obtaining Successful Treatment

    Success on the Investigator Global Assessment (IGA) scale is defined as clear or almost clear with an improvement of at least two grades from baseline. IGA scores range from 0-4: 0=Clear 1. Almost Clear 2. Mild 3. Moderate 4. Severe

    Time frame: After 26 weeks treatment

Secondary outcomes

  1. Time to Treatment Success

    The time elapsed from the first dose to the time of treatment success, according to the Investigator's Global Assessment (IGA) scale. The total time of treatment was 26 weeks, although Covid-19 visit delays led to an extension of up to 2 weeks (28 weeks total) for some patients. Success on the Investigator Global Assessment (IGA) scale is defined as clear or almost clear with an improvement of at least two grades from baseline. IGA scores range from 0-4: 0=Clear 1. Almost Clear 2. Mild 3. Moderate 4. Severe

    Time frame: From first dose to 26 weeks (± 2 weeks)

  2. Change From Baseline in Investigator's Global Assessment

    The change in grading on the Investigator's Global Assessment (IGA) scale from baseline. IGA scores range from 0-4: 0=Clear 1. Almost Clear 2. Mild 3. Moderate 4. Severe

    Time frame: At baseline and after 26 weeks treatment

  3. Change From Baseline in Facial Angiofibroma Severity Index (FASI)

    The change in grading on the Facial Angiofibroma Severity Index (FASI) from baseline. FASI grades lesions according to their erythema, size and extent by summing the scores of each category. The final FASI scores range from (mild) 2-9 (severe). Erythema Skin color 0 Light Red 1 Red 2 Dark Red/purple 3 Size None 0 Small (\< 5mm) 1 Large (\> 5mm) 2 Confluent 3 Extension \<50 % cheek surface 2 \>50% cheek surface 3

    Time frame: At baseline and after 26 weeks treatment

  4. Subjective (Participant or Parent/Caregiver) Percentage Change Rating Scale

    Percentage change in facial angiofibroma since beginning treatment, as assessed by the participant or parent/caregiver. A large value indicates most improvement to facial angiofibroma (minimum=0, maximum=100). This was a single assessment time-point, where the participant or parent/caregiver estimated the percentage change in the facial angiofibroma lesion appearance from their perspective since baseline.

    Time frame: After 26 weeks treatment

  5. Objective (Clinician) Percentage Change Rating Scale

    Percentage improvement in facial angiofibroma since beginning treatment, as assessed by the clinician. A large value indicates most improvement to facial angiofibroma (minimum=0, maximum=100). This was a single assessment time-point, where clinicians estimated the percentage change in the facial angiofibroma lesion appearance from their perspective since baseline.

    Time frame: After 26 weeks treatment

  6. Categorical Change in Facial Angiofibroma

    Change in facial angiofibroma since beginning treatment on a 5-point scale, as assessed by the participant or parent/caregiver. This was a single assessment time-point, where the participant or parent/caregiver evaluated the change in the facial angiofibroma lesion appearance from their perspective since baseline.

    Time frame: After 26 weeks treatment

07

Results

Posted Aug 14, 2023
Limitations and caveats
Covid-19 pandemic halted recruitment, leading to a smaller number of patients recruited than intended (107/120).

Participant flow

Participant flow — Overall Study
Milestone0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlacebo
Started363338
Completed323135
Not completed423

Outcome measures

PrimaryPercentage of Participants Obtaining Successful Treatment

Success on the Investigator Global Assessment (IGA) scale is defined as clear or almost clear with an improvement of at least two grades from baseline. IGA scores range from 0-4: 0=Clear 1. Almost Clear 2. Mild 3. Moderate 4. Severe

Time frame:
After 26 weeks treatment
Reported as:
Count of participants · Participants
Percentage of Participants Obtaining Successful Treatment
Participants0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlacebo
Percentage of Participants Obtaining Successful Treatment432
SecondaryTime to Treatment Success

The time elapsed from the first dose to the time of treatment success, according to the Investigator's Global Assessment (IGA) scale. The total time of treatment was 26 weeks, although Covid-19 visit delays led to an extension of up to 2 weeks (28 weeks total) for some patients. Success on the Investigator Global Assessment (IGA) scale is defined as clear or almost clear with an improvement of at least two grades from baseline. IGA scores range from 0-4: 0=Clear 1. Almost Clear 2. Mild 3. Moderate 4. Severe

Time frame:
From first dose to 26 weeks (± 2 weeks)
Reported as:
Mean · weeks
Time to Treatment Success
weeks0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlacebo
Time to Treatment Success25.89 ± 0.726.71 ± 0.2819.7 ± 0.22
SecondaryChange From Baseline in Investigator's Global Assessment

The change in grading on the Investigator's Global Assessment (IGA) scale from baseline. IGA scores range from 0-4: 0=Clear 1. Almost Clear 2. Mild 3. Moderate 4. Severe

Time frame:
At baseline and after 26 weeks treatment
Reported as:
Count of participants · Participants
Change From Baseline in Investigator's Global Assessment
Participants0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlacebo
-2432
-116177
0151328
+1001
Missing100
SecondaryChange From Baseline in Facial Angiofibroma Severity Index (FASI)

The change in grading on the Facial Angiofibroma Severity Index (FASI) from baseline. FASI grades lesions according to their erythema, size and extent by summing the scores of each category. The final FASI scores range from (mild) 2-9 (severe). Erythema Skin color 0 Light Red 1 Red 2 Dark Red/purple 3 Size None 0 Small (\< 5mm) 1 Large (\> 5mm) 2 Confluent 3 Extension \<50 % cheek surface 2 \>50% cheek surface 3

Time frame:
At baseline and after 26 weeks treatment
Reported as:
Count of participants · Participants
Change From Baseline in Facial Angiofibroma Severity Index (FASI)
Participants0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlacebo
-5110
-4131
-3631
-21093
-1101317
07414
+1001
+2001
Missing100
SecondarySubjective (Participant or Parent/Caregiver) Percentage Change Rating Scale

Percentage change in facial angiofibroma since beginning treatment, as assessed by the participant or parent/caregiver. A large value indicates most improvement to facial angiofibroma (minimum=0, maximum=100). This was a single assessment time-point, where the participant or parent/caregiver estimated the percentage change in the facial angiofibroma lesion appearance from their perspective since baseline.

Time frame:
After 26 weeks treatment
Reported as:
Mean · Percentage Change
Subjective (Participant or Parent/Caregiver) Percentage Change Rating Scale
Percentage Change0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlacebo
Subjective (Participant or Parent/Caregiver) Percentage Change Rating Scale57.06 ± 4.3654.06 ± 5.2130.84 ± 3.89
SecondaryObjective (Clinician) Percentage Change Rating Scale

Percentage improvement in facial angiofibroma since beginning treatment, as assessed by the clinician. A large value indicates most improvement to facial angiofibroma (minimum=0, maximum=100). This was a single assessment time-point, where clinicians estimated the percentage change in the facial angiofibroma lesion appearance from their perspective since baseline.

Time frame:
After 26 weeks treatment
Reported as:
Mean · Percentage Change
Objective (Clinician) Percentage Change Rating Scale
Percentage Change0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlacebo
Objective (Clinician) Percentage Change Rating Scale47.83 ± 3.8849.39 ± 5.2220.76 ± 4.05
SecondaryCategorical Change in Facial Angiofibroma

Change in facial angiofibroma since beginning treatment on a 5-point scale, as assessed by the participant or parent/caregiver. This was a single assessment time-point, where the participant or parent/caregiver evaluated the change in the facial angiofibroma lesion appearance from their perspective since baseline.

Time frame:
After 26 weeks treatment
Reported as:
Count of participants · Participants
Categorical Change in Facial Angiofibroma
Participants0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlacebo
-1 - Worse100
0 - No Difference0112
+1 - Slightly Better2711
+2 - Moderately Better1379
+3 - Significantly Better16134
Missing452

Adverse events

Collected over 30 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.5% Rapamycin Cream, Topical0/36 (0%)2/36 (5.6%)29/36 (80.6%)
1.0% Rapamycin Cream, Topical0/33 (0%)2/33 (6.1%)27/33 (81.8%)
Placebo0/38 (0%)2/38 (5.3%)27/38 (71.1%)
Most frequent serious events
Most frequent serious events
Event0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlacebo
Constipation, nausea, malnutrition, diarrheaGastrointestinal disorders0/360/332/38
Kidney bleedingRenal and urinary disorders0/361/330/38
Collapsed lungInjury, poisoning and procedural complications0/361/330/38
SeizureNervous system disorders1/360/331/38
Chest painCardiac disorders1/360/330/38
Supraventricular tachycardiaCardiac disorders0/360/331/38
Most frequent other events
Showing 10 of 24
Most frequent other events
Event0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlacebo
PruritusSkin and subcutaneous tissue disorders9/3612/332/38
Skin burning sensationSkin and subcutaneous tissue disorders13/366/335/38
ErythemaSkin and subcutaneous tissue disorders7/366/334/38
Dry SkinSkin and subcutaneous tissue disorders7/365/330/38
Pain of skinSkin and subcutaneous tissue disorders3/364/332/38
SeizureNervous system disorders2/364/330/38
AcneSkin and subcutaneous tissue disorders2/363/332/38
HaemorrhageVascular disorders2/363/332/38
Upper respiratory tract infectionInfections and infestations0/360/333/38
RhinitisInfections and infestations1/362/330/38

Baseline characteristics

Age, Continuous
Age, Continuous(years)0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlaceboTotal
Mean27.8 ± 1525.5 ± 1526.3 ± 13.826.6 ± 14.5
Age, Customized
Age, Customized(Participants)0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlaceboTotal
Age group — 6-11 years64616
Age group — 12-17 years58720
Age group — 18-65 years25212571
Sex: Female, Male
Sex: Female, Male(Participants)0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlaceboTotal
Female21142358
Male15191549
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlaceboTotal
Hispanic or Latino54413
Not Hispanic or Latino31293494
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlaceboTotal
American Indian or Alaska Native1001
Asian75618
Native Hawaiian or Other Pacific Islander0101
Black or African American0101
White28263084
More than one race0000
Unknown or Not Reported0022
Study Site
Study Site(Participants)0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlaceboTotal
Site #00 - ACRI Johns Hopkins0022
Site #01 - University Hospital Brno1001
Site #02 - Children's Health Queensland1102
Site #03 - Christchurch Hospital2237
Site #04 - University of Navarra44311
Site #05 - Mayo Clinic1012
Site #06 - Phoenix Children's Hospital2215
Site #07 - Spectrum Health, Michigan3339
Site #08 - University of California, San Diego3429
Site #09 - University of Virginia1012
Site #10 - University of Pecs1124
Site #11 - Slovakia National Institute of Children's Diseases3227
Site #12 - Bethesda Children's Hospital54716
Site #13 - University of Szeged0000
Site #14 - Clinic of Neurology and Psychiatry for Children and Youth, Belgrade2338
Site #15 - Clinical Center of Serbia2237
Site #16 - National Taiwan University55515
Height
Height(centimeters)0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlaceboTotal
Mean164 ± 17165 ± 16161 ± 17163 ± 17
Weight
Weight(kilograms)0.5% Rapamycin Cream, Topical1.0% Rapamycin Cream, TopicalPlaceboTotal
Mean68.1 ± 22.868.9 ± 24.368.4 ± 25.868.5 ± 24.2

4 further baseline measures are reported on the registry.

08

Study locations

17 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • University of California San Diego
    La Jolla, California 92037, United States
  • All Children's Research Institute
    Saint Petersburg, Florida 33701, United States
  • Spectrum Health
    Grand Rapids, Michigan 49503, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • Children's Health Queensland
    Brisbane, Queensland 4101, Australia
  • Fakultni nemocnice Brno
    Brno, 5HG9+4W, Czechia
  • Bethesda Children's Hospital of the Hungarian Reformed Church
    Budapest, G39Q+49, Hungary
  • University of Pécs
    Pécs, H-7624, Hungary
  • Canterbury District Health Board
    Christchurch, Canterbury 8011, New Zealand
  • Clinic of Neurology and Psychiatry for Children and Youth
    Belgrade, 11000, Serbia
  • Clinical Center of Serbia
    Belgrade, 11000, Serbia
  • Narodný ústav detských chorȏb
    Bratislava, 83340, Slovakia
  • Clinica Universidad de Navarra
    Pamplona, Navarra 31008, Spain
  • Clínica Universidad de Navarra
    Madrid, 28007, Spain
  • National Taiwan University Hospital
    Taipei, Taiwan
09

References and documents

Publications

  • Aitken P, Stanescu I, Boddington L, Mahon C, Fogarasi A, Liao YH, Ivars M, Moreno-Artero E, Trauner D, DeRoos ST, Jancic J, Nikolic M, Balazova P, Price HN, Hadzsiev K, Riney K, Stapleton S, Tollefson MM, Bauer D, Pinkova B, Atkinson H. A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial. Br J Dermatol. 2023 Oct 25;189(5):520-530. doi: 10.1093/bjd/ljad243. PubMed 37463422 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual Participant Data is not planned to be shared with other researchers

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Sep 2022, 37 months.

Results were first posted in Aug 2023, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2019
First posted
Feb 1, 2019
StartActual
Jul 28, 2019
Primary completionActual
Sep 1, 2022
CompletionActual
Sep 1, 2022
Results first posted
Aug 14, 2023
Last update
Sep 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03826628
Lead sponsor
Dermatology Specialties Limited Partnership
Responsible party
Sponsor
First posted
Feb 1, 2019
Start date
Jul 28, 2019
Primary completion
Sep 1, 2022
Completion
Sep 1, 2022
Results posted
Aug 14, 2023
Last update
Sep 8, 2023

Study contacts

Ioana Stanescu
study director · Dermatology Specialties Limited Partnership

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion